MX376077B - Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. - Google Patents

Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.

Info

Publication number
MX376077B
MX376077B MX2015012547A MX2015012547A MX376077B MX 376077 B MX376077 B MX 376077B MX 2015012547 A MX2015012547 A MX 2015012547A MX 2015012547 A MX2015012547 A MX 2015012547A MX 376077 B MX376077 B MX 376077B
Authority
MX
Mexico
Prior art keywords
receptor agonist
trpv2 receptor
cardiac dysfunction
trpv2
administered
Prior art date
Application number
MX2015012547A
Other languages
English (en)
Other versions
MX2015012547A (es
Inventor
Keith W Jones
Jack Rubinstein
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of MX2015012547A publication Critical patent/MX2015012547A/es
Publication of MX376077B publication Critical patent/MX376077B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Descritos en la presente, son invenciones dirigidas a métodos para tratar una disfunción cardiaca diastólica y los síntomas de la misma en un sujeto, que incluyen administrar una cantidad de un agonista del receptor TRPV2 efectiva para tratar la disfunción cardiaca diastólica; el agonista del receptor TRPV2 puede administrarse en por lo menos una de una inyección, oralmente o transdérmicamente; la cantidad del agonista del receptor TRPV2 es suficiente para resultar en un desempeño mejorado en criterios de diagnóstico cuantitativos; en una modalidad, el agonista del receptor TRPV2 se administra durante un período de aproximadamente 8 horas a aproximadamente 24 horas; el agonista del receptor TRPV2 puede usarse para tratamientos a corto plazo, es decir, menos una semana, o puede administrarse en una manera a largo plazo, es decir, durante un período de semanas, meses o incluso años; ejemplos de agonistas del receptor TRPV2 incluyen probenecid, borato de 2-aminoetoxidifenilo, canabinol, canabidiol, y combinaciones de los mismos.
MX2015012547A 2013-03-13 2014-03-13 Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. MX376077B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778826P 2013-03-13 2013-03-13
PCT/US2014/025930 WO2014160153A1 (en) 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist

Publications (2)

Publication Number Publication Date
MX2015012547A MX2015012547A (es) 2016-02-10
MX376077B true MX376077B (es) 2025-03-07

Family

ID=50680137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012547A MX376077B (es) 2013-03-13 2014-03-13 Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.

Country Status (7)

Country Link
US (1) US10583103B2 (es)
EP (1) EP2968238A1 (es)
JP (3) JP2016512564A (es)
AU (1) AU2014244053B2 (es)
CA (1) CA2904671C (es)
MX (1) MX376077B (es)
WO (1) WO2014160153A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
AU2018384096B2 (en) * 2017-12-12 2021-04-15 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
IL291936A (en) * 2019-10-25 2022-06-01 Cardiol Therapeutics Inc Cannabidiol preparations for use in heart conditions
JP2023516284A (ja) * 2020-02-19 2023-04-19 マーチャント，シュリーマ カンナビジオールの組成物および治療的使用
KR20210150011A (ko) * 2020-06-03 2021-12-10 주식회사 삼오파마켐 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법
CN113861633B (zh) * 2021-10-14 2022-12-20 武汉工程大学 一种p-n-b阻燃pbs塑料及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524917A (en) 1969-02-10 1970-08-18 Merck & Co Inc Tablets of magnesium probenecid tetrahydrate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH01211582A (ja) 1988-02-16 1989-08-24 Tanabe Seiyaku Co Ltd ベンゾジオキソール誘導体
DK0603301T3 (da) 1991-09-09 1998-09-14 Warner Lambert Co Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US20030212123A1 (en) 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
WO2002041876A1 (en) 2000-11-22 2002-05-30 Lupin Limited Pharmaceutical composition for controlled release of an active ingredient
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20080051428A1 (en) 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
WO2004058790A1 (ja) 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
ATE405827T1 (de) 2003-09-11 2008-09-15 Takeda Pharmaceutical Screening-verfahren
DE10352511A1 (de) 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen
US20050182011A1 (en) 2003-11-13 2005-08-18 Eric Olson Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
WO2005079795A2 (en) 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
US7375113B2 (en) 2004-03-04 2008-05-20 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
EP2068879A2 (en) 2006-05-02 2009-06-17 Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone drugs and methods of use thereof
JP2009149534A (ja) 2007-12-18 2009-07-09 Japan Health Science Foundation Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法
KR100951656B1 (ko) 2008-02-25 2010-04-07 고려대학교 산학협력단 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제
US8420594B2 (en) 2008-07-17 2013-04-16 INSERM (Institute de la Sante et de la Recherche Medicale) Inhibitors of MRP4 and agents stimulating MRP4 activity for the treatment of cardiac disorders
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8980223B2 (en) 2009-05-07 2015-03-17 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation
US10806711B2 (en) * 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid

Also Published As

Publication number Publication date
JP2024009140A (ja) 2024-01-19
JP2016512564A (ja) 2016-04-28
CA2904671A1 (en) 2014-10-02
CA2904671C (en) 2022-08-30
JP2021042248A (ja) 2021-03-18
EP2968238A1 (en) 2016-01-20
AU2014244053B2 (en) 2018-08-30
US20160008305A1 (en) 2016-01-14
AU2014244053A1 (en) 2015-09-24
US10583103B2 (en) 2020-03-10
WO2014160153A1 (en) 2014-10-02
MX2015012547A (es) 2016-02-10

Similar Documents

Publication Publication Date Title
MX376077B (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
CO2019005236A2 (es) Métodos para tratar afecciones inflamatorias
MX2017005875A (es) Metodos para tratar enfermedades oculares.
CY1125247T1 (el) Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2
CL2017002527A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015).
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
EA201790398A1 (ru) Способы лечения заболевания печени
BR112017006113A2 (pt) combinações sinérgicas de auristatina
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2015008777A (es) Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX365321B (es) Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
MX2020003682A (es) Metodos para tratar enfermedades asociadas con ciliopatias.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.

Legal Events

Date Code Title Description
FG Grant or registration